Effects of concomitant fluvoxamine on the metabolism of alprazolam in Japanese psychiatric patients: interaction with CYP2C19 mutated alleles

  title={Effects of concomitant fluvoxamine on the metabolism of alprazolam in Japanese psychiatric patients: interaction with CYP2C19 mutated alleles},
  author={Yutaro Suzuki and Toshiki Shioiri and Tatsuyuki Muratake and Yoshiaki Kawashima and Satoshi Sato and Mieko Hagiwara and Yoshimasa Inoue and Kazutaka Shimoda and Toshiyuki Someya},
  journal={European Journal of Clinical Pharmacology},
ObjectivesAdministration of fluvoxamine (FLV) with concomitant benzodiazepines is common in clinical situations. We studied the effects of the coadministration of FLV on plasma concentrations of alprazolam (ALP). We also studied the effects ofCYP2C19*2 orCYP2C19*3 on these drug interactions.MethodsThe subjects were 23 Japanese outpatients all concomitantly treated with FLV either before or after monotherapy with ALP. We measured the plasma concentrations of ALP and FLV using a column-switching… Expand
Effects of Concomitant Fluvoxamine on the Plasma Concentration of Etizolam in Japanese Psychiatric Patients: Wide Interindividual Variation in the Drug Interaction
Wide variations were observed in the drug interactions; however, coadministration with fluvoxamine produced significant changes in the plasma concentrations of etizolam (P < 0.0001). Expand
Effect of smoking and CYP2D6 polymorphisms on the extent of fluvoxamine–alprazolam interaction in patients with psychosomatic disease
The extent of interaction between FVX and ALP may be affected by smoking, which alters the C/D ratio of FVZ, and it should be noted that non-smokers may exhibit greater drug interaction than smokers. Expand
Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine.
The magnitude of the contribution of CYP2C19 to the metabolism of (S)-lansoprazole is much greater compared with that of the (R)-enantiomer, and in extensive metabolizers, hepatic CYP1C19 plays an important role in the absorption and elimination of lansopazole, particularly the (S-enantiomers. Expand
Pharmacogenetics in drug regulation: promise, potential and pitfalls
  • R. Shah
  • Medicine
  • Philosophical Transactions of the Royal Society B: Biological Sciences
  • 2005
There is an urgent need for prospective data to determine whether pre-treatment genotyping can improve therapy and whether prescribers adhere to the prescribing information, as much of the benefits of pharmacogenetics will be squandered. Expand
Augmenting selective serotonin reuptake inhibitors with clomipramine in obsessive-compulsive disorder: benefits and risks.
  • C. Andrade
  • Psychology, Medicine
  • The Journal of clinical psychiatry
  • 2013
An evidence-based discussion of the pharmacodynamic and pharmacokinetic adverse effects of the SSRI-clomipramine combination along with suggestions for dosing and monitoring when the combination is used in OCD is presented. Expand
The objectives of the present study were to identify prevalence, levels and predictors of pDDIs in pulmonology, psychiatry, cardiology, pediatrics and internal medicine wards of tertiary care hospital settings in Khyber Pakhtunkhwa, Pakistan and to help physicians and clinical pharmacists to identify and manage p DDIs. Expand
Current awareness: Pharmacoepidemiology and drug safety
  • 2003
In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliographyExpand
Clinically relevant drug interactions in anxiety disorders
Certain drugs used in the treatment of patients with anxiety disorders can interact with other psychotropic drugs and with pharmacological treatments for physical illnesses. There is a need for anExpand
Pharmacogenetic evaluation of adverse events’ risk in patients with alcohol withdrawal syndrome taking bromdihydrochlorphenylbenzodiazepine: The role of CYP2C19 gene polymorphisms
ВВЕДЕНИЕ. Бромдигидрохлорфенилбензодиазепин – отечественный транквилизатор, широко применяемый в психиатрии, неврологии, наркологии и общей медицине. В частности, данный препарат используется приExpand
Central Nervous System Drugs


A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine
The pharmacokinetic and pharmacodynamic interaction between fluvoxamine, a serotonin reuptake inhibitor, and alprazolam, a triazolobenzodiazepine, is assesed and the dosage of alpazolam should be reduced during co-administration with fluVoxamine. Expand
Effect of Carbamazepine on the Single Oral Dose Pharmacokinetics of Alprazolam
The present study suggests that carbamazepine decreases plasma concentration of alprazolam by inducing its metabolism, and supports the previous studies, suggesting that alpazolam is metabolized predominantly by CYP3A4. Expand
Effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam
It is suggested that itraconazole, a potent CYP3A4 inhibitor, increases plasma concentration of alprazolam via its inhibitory effects on alpazolam metabolism, which supports previous studies suggesting that CYP 3A4 is the major enzyme catalyzing the metabolism of al prazol am. Expand
Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine.
Ketoconazole was a potent inhibitor of ALP metabolism in vitro, suggesting that ALP hydroxylation is mediated by the cytochrome P450-3A sub-family, and fluoxetine and sertraline were weak inhibitors. Expand
Effects of Genetically Determined S–Mephenytoin 4–Hydroxylation Status and Cigarette Smoking on the Single–Dose Pharmacokinetics of Oral Alprazolam
It is suggested that neither S–mephenytoin 4–hydroxylation status nor self–reports reports of extensive cigarette smoking has a major impact on the metabolism of alprazolam in humans. Expand
Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants.
In vitro preparations of human liver microsomes were used to study the inhibiting effects of two selective serotonin reuptake inhibitor (SSRI) antidepressants, paroxetine and fluvoxamine, onExpand
Single- and multiple-dose pharmacokinetics of oral alprazolam in healthy smoking and nonsmoking men.
Although not significantly different, alprazolam elimination was more rapid in smokers than in nonsmokers and Steady-state pharmacokinetic values during the multiple-dose phase correlated with values observed following the single dose. Expand
Single- and multiple-dose pharmacokinetics of oral alprazolam in healthy smoking and nonsmoking men.
Steady-state pharmacokinetic values during the multiple-dose phase correlated with values observed following the single dose, and alprazolam elimination was more rapid in smokers than in nonsmokers. Expand
The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans.
It is reported that the principal defect in poor metabolizers is a single base pair (G-->A) mutation in exon 5 of CYP2C19, which creates an aberrant splice site that results in a truncated, non-functional protein. Expand
Drug interactions with newer antidepressants: role of human cytochromes P450.
This review evaluates the clinical implications of the metabolic profiles of the newer antidepressants, the relative activities of various new antidepressants as inhibitors of human cytochrome P450, and the various in vivo and in vitro methodologies that can be used for identification and quantification of drug interactions. Expand